Synthesis and antitumor activity of new amphiphilic alkylglycerolipids substituted with a polar head group, 2-(2-trimethylammonioethoxy)ethyl or a congeneric oligo(ethyleneoxy)ethyl group.
Authors:
- Kiyoshi UkawaKUKiyoshi Ukawa
- Eiko ImamiyaEIEiko Imamiya
- Hiroaki YamamotoHYHiroaki Yamamoto
- Tetsuya AonoTATetsuya Aono
- Yoshio KozaiYKYoshio Kozai
- Tetsuya OkutaniTOTetsuya Okutani
- Hiroaki NomuraHNHiroaki Nomura
- Yoshio HonmaYHYoshio Honma
- Motoo HozumiMHMotoo Hozumi
- Ichiro KudoIKIchiro Kudo
- Keizo InoueKIKeizo Inoue
- 1 January 1989
- journal article
- research article
- Published by Pharmaceutical Society of Japan in Chemical and Pharmaceutical Bulletin
- Vol. 37 (12) , 3277-3285
Abstract
A new series of amphiphilic 1-octadecyl glcyerolipids (eleven compounds, 1a-K) were designed and synthesized, in which the 3-phsophocholine portion of platelet-activating factor (1-alkyl-2-acetyl-sn-glycero-3-phosphocholine, PAF) was replaced by the 2-(2-trimethylammonioethoxy)ethyl group and congeneric groups having oligo(ethylenoxy)ethyl bridges of various lengths at position 3, together with modification at position 2 (lower akyl, acetonyl, acetoacetyl, carboxymethyl and pyrimidin-2-yl groups). These ether lipids, characterized by a nonphosphorus lysoglycerolipid structure, showed potent antitumor activity in vitro (human promyeloicytic leukemia cells, HL-60, and human epidermoid carcinoma cells, KB) and in vivo (mouse sarcoma S180 and mouse mammary carcinoma MM46). Maximal in vitro potency was obtained with 1-O-octadecyl-2-O-(2-pyrimidinyl)-3-O-[2,-(2-trimethylammonioethoxy)ethyl]glycerol (1g; IC50 values for both HL-60 and KB were 0.32 .mu.g/ml, indicating a higher activity than alkyl-lysophospholipid, ET18-OME). Several appropriately 2-substituted 1-octadecylglycerolipids with the 3-[2-(2-trimethylammonioethoxy)ethyl] group (e.g., methyl,1b; butyl, 1f; 2,2,2-trifluoroethyl, 1j; and acetonyl, 1k) showed a potent life-span-prolonging effect on mice with ascites sarcoma S180 and on those with mammary carcinoma. MM46, when administered intraperitoneally at 16.5 and 12.5 mg/kg/d, respectively. Compounds 1b and 1k showed definite tumor growth inhibition against solid sarcoma S180 in mice, whether given p.o. or i.v. at 16.5 mg/kg/d. Studies on the structure-activity relationships indicate that the metabolic stability to phsopholipase C or related enzymes is at least partly responsible for the potent antitumor activity of this series of ether lipids.Keywords
This publication has 1 reference indexed in Scilit:
- Syntheses and biological activities of N-alkyl- and N-alkenylcarbamoyl phospholipids.Chemical and Pharmaceutical Bulletin, 1984